Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q3 2024 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2023 Net Income-$25.17M-$25.17MN/M vs Q3 2023 EPS Diluted-$0.89-$0.89N/M vs Q3 2023 Operating Income-$27,347,479N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$27,443,338N/M ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end